ZYNE - ジナ―バ・ファ―マシュ―ティカルズ (Zynerba Pharmaceuticals Inc.) ジナ―バ・ファ―マシュ―ティカルズ

 ZYNEのチャート


 ZYNEの企業情報

symbol ZYNE
会社名 Zynerba Pharmaceuticals Inc (ジナ―バ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジナーバ・ファーマスーティカル(Zynerba Pharmaceuticals Inc.)は専門的医薬品会社である。同社は患者のための経皮合成カンナビノイド治療法の開発・商業化に従事する。開発パイプラインには、ZYN002とZYN001という2つの製品候補が含まれる。ZYN002は非精神活性カンナビノイドである合成カンナビジオール(CBD)であり、特許保護された浸透増強ゲルとして皮膚を通って循環系に入る。ZYN002は難治性てんかん患者、変形性膝関節症患者、脆弱X症候群患者の第Ⅱ相臨床開発段階にある。ZYN001はパッチを通じて循環系への経皮送達を可能にするテトラヒドロカンナビノール(THC)のプロドラッグである。ZYN001は2つの疼痛適応症、線維筋痛症及び末梢神経障害性疼痛を標的とする。   ジナ―バ・ファ―マシュ―ティカルズは米国の特殊医薬品企業。主に、経皮吸収型薬剤デリバリ―システムの開発、商品化に従事する。合成カンナビノイドを利用し、薬剤抵抗性てんかん、脆弱エックス症候群、骨関節炎、線維筋痛、末梢性神経障害性疼痛などの治療に対する薬剤「ZYN002」や「ZYN001」を開発する。本社はペンシルベニア州。   Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.
本社所在地 80 W. Lancaster Avenue Suite 300 Devon PA 19333 USA
代表者氏名 Armando Anido アルマンドアニード
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 484-581-7505
設立年月日 39083
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 22人
url www.zynerba.com
nasdaq_url https://www.nasdaq.com/symbol/zyne
adr_tso
EBITDA EBITDA(百万ドル) -41.02128
終値(lastsale) 7.37
時価総額(marketcap) 129887944.01
時価総額 時価総額(百万ドル) 125.83440
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 82.71935
当期純利益 当期純利益(百万ドル) -40.74337
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Zynerba Pharmaceuticals Inc revenues was not reported. Net loss increased 56% to $24.3M. Higher net loss reflects Foreign exchange (loss) gain decrease from $285K (income) to $309K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.24 to -$1.80.

 ZYNEのテクニカル分析


 ZYNEのニュース

   Boom Or Bust: What Are Zynerba Pharmaceuticals Inc.s (NASDAQ:ZYNE) Future Prospects?  2021/12/11 15:30:00 Marketing Sentinel
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)s traded shares stood at 0.45 million during the last session, with the companys beta value hitting 2.29. At the close of trading, the stocks price was $3.32, to imply a decrease of -3.77% or -$0.13 in intraday trading. The ZYNE shares 52-week high remains $9.00, putting it -171.08% down since that Boom Or Bust: What Are Zynerba Pharmaceuticals Inc.s (NASDAQ:ZYNE) Future Prospects? Read More »
   Zacks: Brokerages Expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to Post -$0.26 EPS  2021/12/09 20:08:42 Transcript Daily
Equities analysts predict that Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) will report earnings of ($0.26) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Zynerba Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.28). Zynerba Pharmaceuticals reported earnings per share of []
   Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium  2021/12/06 12:00:00 Intrado Digital Media
DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021. The presentation can be accessed by registering for free at https://synchronysymposium.com/ . A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ .
   Charles Schwab Investment Management Inc. Takes $96,000 Position in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)  2021/12/03 09:40:46 Dakota Financial News
Charles Schwab Investment Management Inc. acquired a new stake in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) during the second quarter, Holdings Channel reports. The institutional investor acquired 18,093 shares of the companys stock, valued at approximately $96,000. Several other institutional investors and hedge funds also recently modified their holdings of the company. Goldman Sachs Group Inc. boosted []
   Glistering Stock: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Regis Corporation (NYSE:RGS)  2021/11/30 10:40:57 Stock Equity
Zynerba Pharmaceuticals, Inc. (ZYNE) with the stream of -2.22% also noticed, India Regis Corporation (RGS) encountered a rapid change of -3.46% in the last hour of Mondays trading session. Zynerba The post Glistering Stock: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Regis Corporation (NYSE:RGS) appeared first on Stocks Equity .
   Swiveling stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -1.77%), Merck & Co., Inc. (NYSE:MRK 0.18%)  2021/09/05 23:29:48 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Swiveling stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -1.77%), Merck & Co., Inc. (NYSE:MRK 0.18%) appeared first on Stocks Equity .
   Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference  2021/09/02 11:30:00 Intrado Digital Media
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually September 13-15, 2021.
   Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021  2021/09/02 11:00:00 Intrado Digital Media
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at http://zynerba.com/publications/ . Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/ .
   Arena Pharma, GrowGen & HEXO Among Top Cannabis Stock Movers On August 23, 2021  2021/08/24 00:02:08 Benzinga
GAINERS: iAnthus Capital Hldgs (OTC: ITHUF ) shares closed up 35.27% at $0.28 with an estimated market cap of $48,870,997. Aleafia Health (OTC: ALEAF ) shares closed up 18.23% at $0.27 with an estimated market cap of $89,868,989. Item 9 Labs (OTC: INLB ) shares closed up 17.65% at $2 with an estimated market cap of $184,419,042. Tetra Bio Pharma (OTC: TBPMF ) shares closed up 10.78% at $0.24 with an estimated market cap of $96,530,242. Neptune Wellness Solns (NASDAQ: NEPT ) shares closed up 9.76% at $0.66 with an estimated market cap of $110,369,189. HEXO (NYSE: HEXO ) shares closed up 9.7% at $2.55 with an estimated market cap of $387,927,112. Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 9.19% at $51.21 with an estimated market cap of $3,127,620,843. Urban-gro (NASDAQ: UGRO ) shares closed up 7.73% at $13.79 with an estimated market cap of $144,967,581. OrganiGram Holdings (NASDAQ: OGI ) shares closed up 7.63% at $2.54 with an estimated market cap of $758,882,716. 22nd Century Group (NASDAQ: XXII ) shares closed up 7.18% at $3.73 with an estimated market cap of $607,003,351.
   Hot Stock of the Day: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), New York Community Bancorp, Inc. (NYSE:NYCB)  2021/08/13 22:58:41 Stock Equity
Zynerba Pharmaceuticals, Inc. (ZYNE) with the stream of -9.01% also noticed, India New York Community Bancorp, Inc. (NYCB) encountered a rapid change of -0.20% in the last hour of Fridays The post Hot Stock of the Day: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), New York Community Bancorp, Inc. (NYSE:NYCB) appeared first on Stocks Equity .
   Hilly Stock: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Callon Petroleum Company (NYSE:CPE)  2021/06/20 22:52:50 Stock Equity
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) with the stream of -1.97% also noticed, India Callon Petroleum Company (NYSE:CPE) encountered a rapid change of 0.08% in the last hour of trading session. Zynerba The post Hilly Stock: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Callon Petroleum Company (NYSE:CPE) appeared first on Stocks Equity .
   Trending Stock to Observe: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Ampio Pharmaceuticals, Inc. (AMEX:AMPE)  2021/06/17 23:41:38 Stock Equity
Zynerba Pharmaceuticals, Inc. (ZYNE) with the stream of -1.79% also noticed, India Ampio Pharmaceuticals, Inc. (AMPE) encountered a rapid change of -1.67% in the last hour of Thursdays trading session. The post Trending Stock to Observe: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Ampio Pharmaceuticals, Inc. (AMEX:AMPE) appeared first on Stocks Equity .
   Analysts Recommendation in Spotlight: Huntington Bancshares Incorporated (NASDAQ:HBAN), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)  2021/06/16 21:43:45 Stock Equity
Huntington Bancshares Incorporated (NASDAQ:HBAN) with the stream of -0.62% also noticed, India Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) encountered a rapid change of 3.13% in the last hour of Wednesdays trading session. The post Analysts Recommendation in Spotlight: Huntington Bancshares Incorporated (NASDAQ:HBAN), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) appeared first on Stocks Equity .
   In the clinic for June 14, 2021  2021/06/14 15:00:00 BioWorld
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adamis, Astrazeneca, Celltrion, Daiichi, Eyegate, G1, Immvira, Novan, Novavax, Oxthera, Precigen, Roche, Scholar Rock, Terns, Tyme, Vertex, Zynerba.
   Zynerba''s Zygel Improves Sleep In Children With Severe Epilepsies  2021/06/11 18:44:38 Benzinga
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting. The treatment was associated with improved sleep in children Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジナ―バ・ファ―マシュ―ティカルズ ZYNE Zynerba Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)